Physician profile
Michael R Bauer
NPI 1205832128
$11,138.89
in general payments reported to CMS, 2019-2025
36 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $972 · 2021: $588 · 2022: $779 · 2023: $3,693 · 2024: $3,001 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715 · Consulting Fee: $1,837 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Travel and Lodging: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,714.73 |
| Consulting Fee | $1,837.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Travel and Lodging | $320.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $3,513.91 | 2022-2025 | Ffrct |
| Boston Scientific Corporation | $1,943.09 | 2019-2024 | Watchman Access System, Watchman Flx, Opticross |
| Ge Healthcare | $908.00 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $900.11 | 2019-2025 | |
| Edwards Lifesciences Corporation | $614.47 | 2019-2024 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $479.36 | 2022-2025 | Mitraclip, Cardiomems, Coroflow |
| Amgen INC. | $340.15 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $334.88 | 2019-2024 | Xarelto |
| Pfizer INC. | $292.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $255.54 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.23 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $208.40 | 2019-2025 | Lokelma, Farxiga |
| Esperion Therapeutics, INC. | $194.51 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $146.02 | 2023-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.65 | 2019-2024 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $93.48 | 2025 | |
| Novo Nordisk INC | $92.77 | 2022-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $70.25 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $63.62 | 2024 | |
| Sanofi-Aventis U.S. LLC | $44.56 | 2019-2024 | |
| Lundbeck LLC | $39.15 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $26.61 | 2025 | Onpattro |
| Teleflex LLC | $26.51 | 2023 | Turnpike |
| Bridgebio Pharma, INC. | $23.27 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $20.75 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.69 | 2024 | |
| Lilly USA, LLC | $19.28 | 2025 | Mounjaro, Zepbound |
| Chiesi USA, INC. | $17.65 | 2024 | Cleviprex, Kengreal |
| Merck Sharp & Dohme LLC | $17.02 | 2024 | Verquvo |
| Amarin Pharma, INC. | $16.13 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $13.15 | 2023 | Arcalyst |
| Tactile Systems Technology INC | $12.06 | 2019 | |
| Medtronic Vascular, INC. | $12.06 | 2020 | |
| Cardinal Health 200 LLC | $11.87 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.